AZ announces US fast track designation for IL-5 inhibitor Fasenra
Designation granted for the treatment of eosinophilic gastritis with or without eosinophilic gastroenteritis
Read More
Tag: Fasenra
AZ’s Fasenra hits the mark in phase IIIb asthma trial
Drug significantly eliminated oral corticosteroid (OCS) in OCS-dependent asthma patients
Read More
AZ Fasenra shows benefit in chronic rhinosinusitis with nasal polyps
The drug reduced the size of nasal polyps and reduced nasal blockage
Read More
AZ’s Fasenra study confirms robust efficacy in eosinophilic asthma
Drug reduced annual rate of asthma exacerbations by 49%
Read More
FDA green light for Fasenra
Currently there are no FDA-approved treatments for eosinophilic oesophagitis.
Read More
AZ’s Fasenra shows promise in hypereosinophilic syndrome
The drug is AstraZeneca’s first respiratory biologic.
Read More
Fasenra granted Orphan Drug Designation by FDA
AstraZeneca’s Fasenra has been awarded Orphan Drug Designation in the US for the treatment of hypereosinophilic syndrome (HES).
Read More
NICE recommends Fasenra injection as asthma alternative
The National Institute for Health and Care Excellence (NICE) has recommended that a potentially life-changing treatment be available to people with a severe form of asthma on the NHS in England and Wales.
Read More
US grants AZ’ Fasenra orphan drug status for rare autoimmune disease
US regulators have granted AstraZeneca’s Fasenra Orphan Drug Designation for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare and potentially fatal autoimmune disease.
Read More
AZ books sales growth for the third quarter
AstraZeneca’s product sales returned to growth in the third quarter, with new medicines and emerging markets driving performance.
Read More
AZ’ Fasenra shows long-term efficacy in eosinophilic asthma
AstraZeneca has unveiled data from a Phase III extension trial highlighting the efficacy of biologic Fasenra as an add-on maintenance treatment in patients with severe eosinophilic asthma.
Read More
NICE backs AZ’ asthma biologic Fasenra
AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
